NEW YORK (Reuters Health)—A six-month assessment of children with pediatric inflammatory multisystem syndrome temporally associated with COVID-19 disease (PIMS-TS) show generally favorable outcomes, but also a range of lingering issues. Cardiac, gastrointestinal, renal, hematology and otolaryngology problems largely resolved at six months, but muscular fatigue and emotional lability were common. Long-term, serious end-organ damage occurred…
U.S. to Announce New Warning on J&J Coronavirus Vaccine for Guillain-Barré Syndrome
(Reuters)—The U.S. Food & Drug Administration (FDA) is expected to announce a new warning on Johnson & Johnson’s (J&J’s) coronavirus vaccine related to a rare autoimmune disorder, The Washington Post reported on Monday, citing four people familiar with the matter.1 According to The Post, about 100 preliminary reports of Guillain-Barré syndrome have been detected in the…
Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination
(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1 A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who…
Researchers Explore Response to COVID-19 Vaccines in the Elderly
A delayed second dose of an mRNA vaccine may provide better protection against COVID-19 in elderly patients.
Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations
Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.
COVID-19 Puts Latino Patients with Rheumatic Disease at Risk of a Disease Flare
In their new study, Fike et al. found Latino patients with rheumatic diseases have a higher rate of COVID-19 than the general Latino population. Obesity is a risk factor for COVID-19, and COVID-19 is a risk factor for rheumatic disease flare.
Tofacitinib Promising for COVID-19 Pneumonia
(Reuters)—Pfizer Inc. said on June 16 its oral rheumatoid arthritis (RA) drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s main goal. Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published…
Town Hall Provides Tools to Guide Patients Unsure About COVID-19 Vaccination
The ACR’s May 13 virtual town hall highlighted effective approaches rheumatology providers can take to convince patients to be vaccinated against COVID-19.
How Immunosuppression May Affect COVID-19 Vaccine Response
Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immunosuppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…
A Unified Advocacy Voice for Rheumatology
One thing that became clear very quickly this past year was that the COVID-19 pandemic would change the way we deliver care to patients. What has not changed amid an evolving healthcare landscape is our driving focus to ensure our patients’ access to rheumatology care and the availability of state-of-the-art treatments. We know you share…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 27
- Next Page »